First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma

被引：1
|
作者：
Tsimafeyeu, Ilya [1 ]
Tjulandin, Sergei [1 ]
机构：
[1] Russian Soc Clin Oncol, Moscow, Russia
来源：
BJU INTERNATIONAL | 2019年 / 123卷 / 04期
关键词：
urothelial carcinoma; atezolizumab; pembrolizumab; cisplatin-ineligible patients; PD-L1; testing; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; MULTICENTER; ATEZOLIZUMAB; CHEMOTHERAPY;
D O I：
10.1111/bju.14627
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：563 / 565
页数：3
相关论文
共 50 条
  • [21] PD-L1 assessment in urothelial carcinoma: a practical approach
    Eckstein, Markus
    Cimadamore, Alessia
    Hartmann, Arndt
    Lopez-Beltran, Antonio
    Cheng, Liang
    Scarpelli, Marina
    Montironi, Rodolfo
    Gevaert, Thomas
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (22)
  • [22] A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
    Khaki, Ali Raza
    Li, Ang
    Diamantopoulos, Leonidas N.
    Miller, Natalie J.
    Carril-Ajuria, Lucia
    Castellano, Daniel
    De Kouchkovsky, Ivan
    Koshkin, Vadim
    Park, Joseph
    Alva, Ajjai
    Bilen, Mehmet A.
    Stewart, Tyler
    Santos, Victor
    Agarwal, Neeraj
    Jain, Jayanshu
    Zakharia, Yousef
    Morales-Barrera, Rafael
    Devitt, Michael
    Nelson, Ariel
    Hoimes, Christopher J.
    Shreck, Evan
    Gartrell, Benjamin A.
    Sankin, Alex
    Tripathi, Abhishek
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Rodriguez-Vida, Alejo
    Drakaki, Alexandra
    Liu, Sandy
    Kumar, Vivek
    Lythgoe, Mark P.
    Pinato, David J.
    Murgic, Jure
    Frobe, Ana
    Joshi, Monika
    Velho, Pedro Isaacsson
    Hahn, Noah
    Buznego, Lucia Alonso
    Duran, Ignacio
    Moses, Marcus
    Barata, Pedro
    Galsky, Matthew D.
    Sonpavde, Guru
    Yu, Evan Y.
    Shankaran, Veena
    Lyman, Gary H.
    Grivas, Petros
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (03): : 464 - 472
  • [23] Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis
    Huang, J.
    Teng, X.
    CURRENT ONCOLOGY, 2020, 27 (06) : E656 - E663
  • [24] Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series
    Jindal, Tanya
    Chou, Jonathan
    Friedlander, Terence
    Barata, Pedro C.
    Koshkin, Vadim S.
    CLINICAL GENITOURINARY CANCER, 2022, 20 (02) : 189 - 194
  • [25] Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
    Sun, Fengze
    Wang, Dawei
    Liu, Aina
    Wang, Tianqi
    Zhang, Dongxu
    Yao, Huibao
    Sun, Kai
    Zhou, Zhongbao
    Lu, Guoliang
    Wu, Jitao
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [26] Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma
    Mansinho, Andre
    Cruz, Andreia
    Marconi, Lorenzo
    Pinto, Cidalia
    Augusto, Isabel
    ADVANCES IN THERAPY, 2023, 40 (10) : 4134 - 4150
  • [27] First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis
    Mori, Keiichiro
    Pradere, Benjamin
    Moschini, Marco
    Mostafaei, Hadi
    Laukhtina, Ekaterina
    Schuettfort, Victor M.
    Motlagh, Reza Sari
    Soria, Francesco
    Teoh, Jeremy Y. C.
    Egawa, Shin
    Powles, Thomas
    Shariat, Shahrokh F.
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 35 - 48
  • [28] Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
    Chen, Hsiao-Ling
    Chan, Vinson Wai-Shun
    Tu, Yu-Kang
    Chan, Erica On-Ting
    Chang, Hsiu-Mei
    Juan, Yung-Shun
    Teoh, Jeremy Yuen-Chun
    Lee, Hsiang Ying
    CANCERS, 2021, 13 (06)
  • [29] Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    La-Beck, Ninh M.
    Nguyen, Dung T.
    Le, Alex D.
    Alzghari, Saeed K.
    Trinh, Saralinh T.
    PHARMACOTHERAPY, 2020, 40 (03): : 239 - 255
  • [30] Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial
    Grivas, Petros
    Park, Se Hoon
    Voog, Eric
    Caserta, Claudia
    Gurney, Howard
    Bellmunt, Joaquim
    Kalofonos, Haralabos
    Ullen, Anders
    Loriot, Yohann
    Sridhar, Srikala S.
    Yamamoto, Yoshiaki
    Petrylak, Daniel P.
    Sternberg, Cora N.
    Gupta, Shilpa
    Huang, Bo
    Costa, Nuno
    Laliberte, Robert J.
    di Pietro, Alessandra
    Valderrama, Begona P.
    Powles, Thomas
    EUROPEAN UROLOGY, 2023, 84 (01) : 95 - 108
12345